

# Efficiency of aseptic open vitrification in ultraviolet-sterilised Liquid Nitrogen and hermetical cryostorage of human oocytes

**Submission date**  
19/07/2010

**Recruitment status**  
No longer recruiting

☐ Prospectively registered

☐ Protocol

**Registration date**  
30/07/2010

**Overall study status**  
Completed

☐ Statistical analysis plan

☒ Results

**Last Edited**  
07/02/2012

**Condition category**  
Pregnancy and Childbirth

☐ Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Lodovico Parmegiani

### Contact details

GynePro Medical Centers  
Reproductive Medicine Unit  
Via T. Cremona 8  
Bologna  
Italy  
40137  
+39 (0)347 472 5674  
l.parmegiani@gynepro.it

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

## Study information

### Scientific Title

Efficiency of aseptic open vitrification in ultraviolet-sterilised Liquid Nitrogen and hermetical cryostorage of human oocytes: a prospective randomised study between fresh versus vitrified /warmed sibling oocytes.

### Study objectives

The objective of the present study is to demonstrate that ultraviolet (UV) sterilisation of Liquid Nitrogen (LN2) is not detrimental and can be safely used for aseptic vitrification of human oocytes. In addition, in this study, we also describe a system to avoid hypothetical contamination during cryostorage, by enclosing the vitrified oocytes in a sterile device for hermetic isolation inside cryobanks. With this article we wish to report for the first time a safe method for aseptic open vitrification and hermetical cryostorage of human oocytes in accordance with the European directives on tissue manipulation. In order to assess the safety of this kind of vitrification/storage procedure we performed a randomised comparison between fresh and vitrified/warmed sibling-oocytes on infertile couples coming to our centre for intracytoplasmic sperm injection (ICSI) treatment.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

The institutional medical ethics committee of GynePro Medical Center approved on the 16th of March 2008

### Study design

Single centre prospective randomised study

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

Not available in web format, please use contact details below to request a patient information sheet

### Health condition(s) or problem(s) studied

Intracytoplasmic sperm injection (ICSI), aseptic open oocyte vitrification in UV-sterilised liquid nitrogen, hermetical cryostorage

## Interventions

After retrieval oocytes were denuded and then evaluated to assess their nuclear maturation stage. The oocytes that had released the first polar body (metaphase II - MII) underwent a strict selection by morphological features (zona pellucida thickness, perivitelline space size, oocyte shape, cytoplasm colour and granularity, presence of vacuoles and first polar body morphology). Immediately after decumulation and quality evaluation, the high quality MII oocytes were put in progressively-numbered culture droplets and randomised for ICSI; the supernumerary sibling MII oocytes were vitrified. Since at the beginning of this study the Italian IVF law allowed the injection of maximum three oocytes (Benagiano and Gianaroli, 2004), between April 2008 and 8 April 2009 three MII oocytes were randomised for ICSI and the supernumerary sibling oocytes were vitrified. Randomisation was performed by a different embryologist to the operator who performed oocyte denudation using a specific software ([www.randomizer.org](http://www.randomizer.org)). Since 9 April 2009 - due to changes in the Italian law (Benagiano and Gianaroli, 2010) - the number of oocytes to randomise for ICSI or vitrification has been defined following our centres guideline based on: female age at oocyte recovery and semen parameters, but generally not more than 6 oocytes are injected.

Only the first warming cycle per patient was included in the study: from the beginning of the study to 8 April 2009 maximum 3 random warmed oocytes were injected by ICSI; from 9 April 2009 the number of warmed oocytes to inject has defined following our centres guideline.

LN2 sterilisation via UV irradiation was performed by administration of 660,000  $\mu\text{W}/\text{cm}^2$ .

Cryotop (Kitazato BioPharma Co, Fuji-Shizuoka, Japan) oocyte vitrification was performed at room temperature in a 'home made' solution comprising 15% dimethylsulphoxide (DMSO- D 2438 Sigma Aldrich, Steinheim, Germany), 15% ethylene glycol (EG 10.246-6 Sigma Aldrich) and 0.5 mol/L sucrose (Sigma Aldrich), after a gradual initial equilibration of 15 minutes in a solution comprising 7.5% DMSO and 7.5% EG (Kuwayama et al, 2005, Rienzi et al., 2009). For the ultra-rapid cooling, the Cryotops - containing 1-2 oocytes- were plunged into UV-sterilised LN2 . and closed with their plastic caps. Then, the Cryotops of each patient were enclosed in 'home made' hermetical aluminium cylindric containers (high security goblets). which can contain up to 6 Cryotops each. These goblets had been previously submerged vertically in LN2 in order to avoid the infiltration of LN2 and checked for an inner temperature of  $-196^{\circ}\text{C}$  at the end of UV-sterilisation process. The Cryotops were inserted into the 'high security goblets' taking care to keep the Cryotop strip containing the oocyte in the nitrogen vapour phase above the LN2. Finally, the goblets were hermetically closed with sterilised caps and polipropilene adhesive tape (Scotch® 3M Italia, Pioltello MI, Italy).

Before the rapid warming, the hermetical goblets containing the Cryotops were opened into the UV-sterilised LN2. The caps of the Cryotops were removed in the LN2, and each open carrier was submerged in 1 mL of warming solution containing 1 M sucrose at  $37^{\circ}\text{C}$ . Then, the oocytes were incubated at room temperature for 3 minutes first in 0.5 M and subsequently in 0.25 M and finally washed for 4 minutes in basic medium (PBS D8662 Sigma Aldrich, supplemented with 20% EHSA Conception Technologies, San Diego CA, USA) before culture. Warmed oocytes were considered to have survived in absence of negative characteristics: dark or contracted ooplasm, vacuolization, cytoplasmic leakage, abnormal perivitelline space, cracked zona pellucida. After 1-2 hours post-warm culture the surviving oocytes were inseminated by ICSI.

## Intervention Type

Other

**Phase**

Not Applicable

**Primary outcome measure**

1. Oocyte fertilisation rate
2. Embryo cleavage rate
3. Top-quality embryo rate

**Secondary outcome measures**

No secondary outcome measures

**Overall study start date**

01/04/2008

**Completion date**

30/05/2010

**Eligibility****Key inclusion criteria**

1. Women enrolled in the vitrification programme at GynePro medical centre undergoing ICSI with ejaculated spermatozoa
2. Not older than 41 years
3. At least six mature-Methaphase II oocytes at retrieval

This study compares the outcome of 31 warmed ICSI cycles performed from January 2009 to May 2010 with the outcome of fresh sibling oocytes ICSI performed from April 2008 to March 2010

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Female

**Target number of participants**

30

**Key exclusion criteria**

1. Women older than 41 years old
2. Women with less than six mature-MII oocytes at retrieval
3. Patients with male partners with testicular spermatozoa or severe oligoasthenoteratozoospermia (motile sperm count  $\leq$  500.000/mL after sperm preparation)

**Date of first enrolment**

01/04/2008

**Date of final enrolment**

30/05/2010

## **Locations**

### **Countries of recruitment**

Italy

### **Study participating centre**

**GynePro Medical Centers**

Bologna

Italy

40137

## **Sponsor information**

### **Organisation**

GynePro Medical Centers (Italy)

### **Sponsor details**

Via T. Cremona 8

Bologna

Italy

40137

+39 (0)347 472 5674

[l.parmegiani@gynepro.it](mailto:l.parmegiani@gynepro.it)

### **Sponsor type**

Hospital/treatment centre

### **Website**

<http://www.gynepro.it>

### **ROR**

<https://ror.org/03segdh23>

## **Funder(s)**

### **Funder type**

Hospital/treatment centre

### **Funder Name**

GynePro Medical Centers (Italy)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/10/2011		Yes	No